Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Pathology & Oncology Research
Erschienen in: Pathology & Oncology Research 2/2013

01.04.2013 | Review

Calreticulin and Cancer

verfasst von: Mohammadreza Zamanian, Abhi Veerakumarasivam, Syahril Abdullah, Rozita Rosli

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Calreticulin (CRT) as a multi-functional endoplasmic reticulum protein is involved in a spectrum of cellular processes which ranges from calcium homeostasis and chaperoning to cell adhesion and finally malignant formation and progression. Previous studies have shown a contributing role for CRT in a range of different cancers. This present review will focus on the possible roles of CRT in the progression of malignant proliferation and the mechanisms involved in its contribution to cancer invasion.
Literatur
1.
Michalak M et al (1999) Calreticulin: one protein, one gene, many functions. Biochem J 344(2):281–292CrossRefPubMed
2.
Goicoechea S et al (2002) The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J Biol Chem 277(40):37219–37228CrossRefPubMed
3.
Michalak M et al (1992) Calreticulin. Biochem J 285(3):681–692PubMed
4.
Michalak M, Robert Parker JM, Opas M (2002) Ca2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell Calcium 32(5–6):269–278CrossRefPubMed
5.
Rojiani MV et al (1991) In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits. Biochemistry 30:9859–9866CrossRefPubMed
6.
Burns K et al (1994) Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 367(6462):476–480CrossRefPubMed
7.
Gelebart P, Opas M, Michalak M (2005) Calreticulin, a Ca2+−binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37(2):260–266CrossRefPubMed
8.
Qiu Y, Michalak M (2009) Transcriptional control of the calreticulin gene in health and disease. Int J Biochem Cell Biol 41(3):531–538CrossRefPubMed
9.
Gold LI et al (2010) Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 24(3):665–683CrossRefPubMed
10.
Nanney LB et al (2008) Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol 173(3):610–630CrossRefPubMed
11.
Gu VY et al (2008) Calreticulin in human pregnancy and pre-eclampsia. Mol Hum Reprod 14(5):309–315CrossRefPubMed
12.
Pagh R et al (2008) The chaperone and potential mannan-binding lectin (MBL) co-receptor calreticulin interacts with MBL through the binding site for MBL-associated serine proteases. FEBS J 275(3):515–526CrossRefPubMed
13.
Yokoyama M, Hirata K-I (2005) New function of calreticulin: calreticulin-dependent mRNA destabilization. Circ Res 97(10):961–963CrossRefPubMed
14.
McCauliffe DP et al (1992) The 5’-flanking region of the human calreticulin gene shares homology with the human GRP78, GRP94, and protein disulfide isomerase promoters. J Biol Chem 267(4):2557–2562PubMed
15.
Waser M et al (1997) Regulation of calreticulin gene expression by calcium. J Cell Biol 138(3):547–557CrossRefPubMed
16.
Nguyen TQ, Donald Capra J, Sontheimer RD (1996) Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals. Mol Immunol 33(4–5):379–386CrossRefPubMed
17.
Michalak M et al (2009) Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 417(3):651–666CrossRefPubMed
18.
Qiu Y et al (2008) Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factorsâ€. Biochemistry 47(12):3697–3704CrossRefPubMed
19.
Guo L et al (2001) COUP-TF1 antagonizes Nkx2.5-mediated activation of the calreticulin gene during cardiac development. J Biol Chem 276:2797–2801CrossRefPubMed
20.
Lynch J et al (2005) Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+−dependent signaling cascade. J Cell Biol 170:37–47CrossRefPubMed
21.
Vig S et al (2012) C/EBPα mediates the transcriptional suppression of human calreticulin gene expression by TNFα. Int J Cell Biol 44(1):113–122CrossRef
22.
Opas M et al (1991) Regulation of expression and intracellular distribution of calreticulin, a major calcium binding protein of nonmuscle cells. J Cell Physiol 149(1):160–171CrossRefPubMed
23.
Yoon G-S et al (2000) Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res 60(4):1117–1120PubMed
24.
Gold LI, et al. (2006) Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. The journal of investigative dermatology. Symposium proceedings/the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research 11(1):57–65
25.
Huang J-B et al (2004) Identification of channels promoting calcium spikes and waves in HT1080 tumor cells. Cancer Res 64(7):2482–2489CrossRefPubMed
26.
Pallero MA et al (2008) Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 22(11):3968–3979CrossRefPubMed
27.
Kageyama K et al (2002) Overexpression of calreticulin modulates protein kinase B/Akt signaling to promote apoptosis during cardiac differentiation of cardiomyoblast H9c2 cells. J Biol Chem 277(22):19255–19264CrossRefPubMed
28.
Okunaga T et al (2006) Calreticulin, a molecular chaperone in the endoplasmic reticulum, modulates radiosensitivity of human glioblastoma U251MG cells. Cancer Res 66(17):8662–8671CrossRefPubMed
29.
Lim S, et al. (2008) Enhanced calreticulin expression promotes calcium-dependent apoptosis in postnatal cardiomyocytes. 25:390–396
30.
Bini L et al (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18(15):2832–2841CrossRefPubMed
31.
Chahed K et al (2005) Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int J Oncol 27(5):1425–1431PubMed
32.
Kageyama S et al (2004) Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 50(5):857–866CrossRefPubMed
33.
Ayodele A et al (2000) Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 21(1):1–9
34.
Kim Y et al (2004) Glucoronic acid is a novel inducer of heat shock response. Mol Cell Biochem 259(1):23–33CrossRefPubMed
35.
Hong S-H et al (2004) An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64(15):5504–5510CrossRefPubMed
36.
Du X-L et al (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med 85(8):863–875CrossRefPubMed
37.
Nishimori T et al (2006) Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 6(3):1011–1018CrossRefPubMed
38.
Chen CN et al (2009) Association between color doppler vascularity index, angiogenesis-related molecules, and clinical outcomes in gastric cancer. J Surg Oncol 99(7):402–408CrossRefPubMed
39.
Vougas K et al (2008) Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. J Blacan Union Oncol 13(1):101–107
40.
White TK, Zhu Q, Tanzer ML (1995) Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 270(27):15926–15929CrossRefPubMed
41.
Dissemond J et al (2004) Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett 203(2):225–231CrossRefPubMed
42.
Helbling D et al (2005) CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 106(4):1369–1375CrossRefPubMed
43.
Chen CN et al (2009) Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 16(2):524–533CrossRefPubMed
44.
Lwin Z-M, et al. (2010) Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol
45.
Eric A et al (2009) Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 15(1):89–90CrossRefPubMed
46.
Pabst T et al (2001) AML1-ETO downregulates the granulocytic differentiation factor C/EBP[alpha] in t(8;21) myeloid leukemia. Nat Med 7(4):444–451CrossRefPubMed
47.
Lu Y-C et al (2011) Changes in tumor growth and metastatic capacities of j82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol 179:1425–1433CrossRefPubMed
48.
Hayashi E et al (2005) Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 5(4):1024–1032CrossRefPubMed
49.
Zhu J (1996) Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD/Ro antigen. Clin Exp Immunol 1(103):47–53CrossRef
50.
Alur M et al (2009) Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol 175(2):882–890CrossRefPubMed
51.
Porcellini S et al (2006) Regulation of peripheral T cell activation by calreticulin. J Exp Med 203(2):461–471CrossRefPubMed
52.
Dupuis M et al (1993) The calcium-binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes. J Exp Med 177(1):1–7CrossRefPubMed
53.
Andrin C et al (1998) Interaction between a Ca2+−binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules†. Biochemistry 37(29):10386–10394CrossRefPubMed
54.
Sipione S et al (2005) Impaired cytolytic activity in calreticulin-deficient CTLs. J Immunol 174(6):3212–3219PubMed
55.
56.
Obeid M et al (2007) Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. Cancer Res 67(17):7941–7944CrossRefPubMed
57.
Clarke C, Smyth MJ (2007) Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 25(2):192–193CrossRefPubMed
58.
Zhou P et al (2008) Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood 111(2):549–557CrossRefPubMed
59.
60.
Hayashida Y et al (2006) Calreticulin represses E-cadherin gene expression in Madin-Darby Canine kidney cells via slug. J Biol Chem 281(43):32469–32484CrossRefPubMed
61.
Fresno Vara JA et al (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193–204CrossRefPubMed
62.
Xu Q et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36):5552–5560CrossRefPubMed
63.
Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809CrossRefPubMed
64.
Luo M-L et al (2006) Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66(24):11690–11699CrossRefPubMed
65.
66.
Du XL et al (2009) Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 28(42):3714–3722CrossRefPubMed
67.
Dedhar S et al (1994) Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367(6462):480–483CrossRefPubMed
68.
Green S et al (1988) The N-terminal DNA-binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO J 7(10):3037–3044PubMed
69.
Platet N et al (2000) Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 14(7):999–1009CrossRefPubMed
70.
Lusche DF, Wessels D, Soll DR (2009) The effects of extracellular calcium on motility, pseudopod and uropod formation, chemotaxis, and the cortical localization of myosin II in Dictyostelium discoideum. Cell Motil Cytoskeleton 66(8):567–587CrossRefPubMed
71.
Fache S et al (2005) Calcium mobilization stimulates Dictyostelium discoideum shear-flow-induced cell motility. J Cell Sci 118(15):3445–3458CrossRefPubMed
72.
Chantome A et al (2009) KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 315(20):3620–3630CrossRefPubMed
73.
Titushkin I, Cho M (2009) Regulation of cell cytoskeleton and membrane mechanics by electric field: role of linker proteins. Biophys J 96(2):717–728CrossRefPubMed
74.
Nakamura K et al (2001) Functional specialization of calreticulin domains. J Cell Biol 154(5):961–972CrossRefPubMed
75.
Mesaeli N et al (1999) Calreticulin is essential for cardiac development. J Cell Biol 144(5):857–868CrossRefPubMed
76.
Camacho P, Lechleiter JD (1995) Calreticulin inhibits repetitive intracellular Ca2+ waves. Cell 82(5):765–771CrossRefPubMed
77.
Arnaudeau S et al (2002) Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria. J Biol Chem 277(48):46696–46705CrossRefPubMed
78.
Orr AW et al (2003) Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J Cell Sci 116(14):2917–2927CrossRefPubMed
79.
Li SS, Forslöw A, Sundqvist K-G (2005) Autocrine regulation of T cell motility by calreticulin-thrombospondin-1 interaction. J Immunol 174(2):654–661PubMed
Metadaten
Titel
Calreticulin and Cancer
verfasst von
Mohammadreza Zamanian
Abhi Veerakumarasivam
Syahril Abdullah
Rozita Rosli
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2013
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9600-2

Weitere Artikel der Ausgabe 2/2013

Pathology & Oncology Research 2/2013 Zur Ausgabe

Research

Association of BLCA-4 Hypomethylation in Blood Leukocyte DNA and the Risk of Bladder Cancer in a Chinese Population

Research

The Expression of Non-Mast Histamine in Tumor Associated Microvessels in Human Colorectal Cancers

Research

Significance of AgNORs and Ki-67 Proliferative Markers in Differential Diagnosis of Thyroid Lesions

Research

4-1BB Protects Dendritic Cells from Prostate Cancer-Induced Apoptosis

Research

Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC

Research

DARPP32, STAT5 and STAT3 mRNA Expression Ratios in Glioblastomas are Associated with Patient Outcome

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise